Clinical Trials
18 trialsNCT05747625 2026-05-08
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
NCT05786924 2026-04-21
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Phase 1/2 Recruiting
NCT05901545 2026-03-05
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
NCT05423197 2025-07-16
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
Stanford University
Phase 2 Not yet recruiting
NCT00820248 2023-08-22
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT03733210 2023-05-19
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Stanford University
Phase 1 Completed
NCT00446446 2022-10-05
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
Phase 2 Completed
NCT02643056 2021-10-27
S10PANI01
Southern Europe New Drug Organization
Phase 2 Completed
NCT01264328 2019-04-16
VECTITAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Completed
NCT00756444 2018-11-15
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed
NCT00500760 2018-10-17
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Amgen
Phase 2 Completed
NCT00798655 2017-10-03
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00547157 2017-03-15
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed
NCT00513383 2017-03-01
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Massachusetts General Hospital
Phase 1 Completed
NCT01634880 2016-05-23
Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT01312493 2015-08-28
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01305772 2014-08-29
TOP0901
Duke University
Phase 2 Terminated
NCT01142414 2012-01-16
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Withdrawn